Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apolipoprotein CIII: 42 years old and even more interesting.

× No keyword cloud information.

24 in total

1. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors: Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal: J Lipid Res Date: 2017-02-03 Impact factor: 5.922

Review 2. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors: Richard Kones
Journal: Vasc Health Risk Manag Date: 2013-10-21

3. Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?

Authors: Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal: J Lipid Res Date: 2011-03-24 Impact factor: 5.922

4. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors: Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal: Arterioscler Thromb Vasc Biol Date: 2015-06-11 Impact factor: 8.311

Review 5. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.

Authors: Natalia A Rocha; Cara East; Jun Zhang; Peter A McCullough
Journal: Curr Atheroscler Rep Date: 2017-11-09 Impact factor: 5.113

6. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors: Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal: Nat Med Date: 2017-08-21 Impact factor: 53.440

Apolipoprotein CIII: 42 years old and even more interesting.

1. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Review 2. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

3. Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?

4. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Review 5. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.

6. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

7. APOC3, coronary disease, and complexities of Mendelian randomization.

8. Metabolism of Triglyceride-Rich Lipoproteins.

9. Apolipoprotein C-III Nanodiscs Studied by Site-Specific Tryptophan Fluorescence.

10. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.